Stoke Therapeutics Inc logo

Stoke Therapeutics Inc

$ 18.72 -0.19 (-1%) 12:07 PM EST
P/E:
At Loss
P/B:
3.25
Market Cap:
$ 733.02M
Enterprise V:
$ 471.87M
Volume:
39.95K
Avg Vol (2M):
204.17K
Also Trade In:
Volume:
39.95K
Market Cap $:
733.02M
PE Ratio:
At Loss
Avg Vol (2-Month):
204.17K
Enterprise Value $:
471.87M
PB Ratio:
3.25
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Stoke Therapeutics Inc
NAICS : 325412 SIC : 2834
45 Wiggins Avenue, Bedford, MA, USA, 01730
Description
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.
Name Current Vs Industry Vs History
Cash-To-Debt 132.51
Equity-to-Asset 0.74
Debt-to-Equity 0.01
Debt-to-EBITDA -0.02
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.72
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 39.38
9-Day RSI 51.39
14-Day RSI 55.47
6-1 Month Momentum % -21.55
12-1 Month Momentum % -40.67

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.46
Quick Ratio 10.46
Cash Ratio 9.97

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6.8

Financials (Next Earnings Date:2022-11-08 Est.)

STOK's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:STOK

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 6.231
EPS (TTM) ($) -2.56
Beta 0.57
Volatility % 47.1
14-Day RSI 55.47
14-Day ATR ($) 1.520747
20-Day SMA ($) 17.785
12-1 Month Momentum % -40.67
52-Week Range ($) 9.545 - 33.0635
Shares Outstanding (Mil) 39.42

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Stoke Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More